Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Sells $3,093,750.00 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Alnylam Pharmaceuticals Stock Up 1.2 %

Shares of Alnylam Pharmaceuticals stock opened at $278.76 on Monday. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The company has a market capitalization of $35.95 billion, a P/E ratio of -106.40 and a beta of 0.34. The business has a 50-day moving average of $247.13 and a two-hundred day moving average of $260.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. During the same quarter in the prior year, the firm posted $1.15 earnings per share. The business’s quarterly revenue was down 33.3% on a year-over-year basis. As a group, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC boosted its position in Alnylam Pharmaceuticals by 11,433.4% during the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after acquiring an additional 135,829 shares during the last quarter. Sanctuary Advisors LLC bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $578,000. Assenagon Asset Management S.A. boosted its stake in shares of Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock worth $4,687,000 after buying an additional 2,285 shares during the last quarter. Toronto Dominion Bank grew its holdings in shares of Alnylam Pharmaceuticals by 27.3% in the 3rd quarter. Toronto Dominion Bank now owns 15,466 shares of the biopharmaceutical company’s stock valued at $4,254,000 after acquiring an additional 3,315 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in Alnylam Pharmaceuticals by 22.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company’s stock worth $20,165,000 after acquiring an additional 13,422 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on ALNY shares. Scotiabank lifted their price objective on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Raymond James increased their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Canaccord Genuity Group boosted their price objective on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $298.61.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.